Publications

  1. Kottschade LA, Grotz TE, Dronca RS, Salomao DR, Pulido JS, Wasif N, Jakub JW, Bagaria SP, Kumar R, Kaur JS, Morita SY, Moran SL, Nguyen JT, Nguyen EC, Hand JL, Erickson LA, Brewer JD, Baum CL, Miller RC, Swanson DL, Lowe V, Markovic SN. Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol. 2014 Dec; 37(6):635-41.
    View PubMed
  2. Jin L, Lloyd RV, Henry MR, Erickson LA, Sebo TJ, Rumilla KM, Zhang J. The Diagnostic Utility of Combination of HMGA2 and IMP3 qRT-PCR Testing in Thyroid Neoplasms. Appl Immunohistochem Mol Morphol. 2014 Oct 29. [Epub ahead of print]
    View PubMed
  3. Erickson LA, Rivera M, Zhang J. Adrenocortical carcinoma: review and update. Adv Anat Pathol. 2014 May; 21(3):151-9.
    View PubMed
  4. Xiong MY, Rabkin MS, Piepkorn MW, Barnhill RL, Argenyi Z, Erickson L, Guitart J, Lowe L, Shea CR, Trotter MJ, Weinstock MA. Diameter of dysplastic nevi is a more robust biomarker of increased melanoma risk than degree of histological dysplasia: a case control study. Journal of the American Academy of Dermatology. 2014.
  5. Asioli S, Erickson LA, Righi A, Lloyd RV. Papillary thyroid carcinoma with hobnail features: histopathologic criteria to predict aggressive behavior. Hum Pathol. 2013 Mar; 44(3):320-8. Epub 2012 Oct 1.
    View PubMed
  6. Thomas L, Moore EJ, McGree ME, Olsen KD, Kasperbauer JL, Erickson LA, Schembri-Wismayer DJ. Prognostic features, human papillomavirus status, and epidermal growth factor receptor expression in oral squamous cell carcinoma in young adults. Am J Otolaryngol. 2012 Nov-Dec; 33(6):650-6. Epub 2012 Mar 03.
    View PubMed
  7. Grotz TE, Mansfield AS, Kottschade LA, Erickson LA, Otley CC, Markovic SN, Jakub JW. In-transit melanoma: an individualized approach. Oncology (Williston Park). 2011 Dec; 25(14):1340-8.
    View PubMed
  8. Palmer SR, Erickson LA, Ichetovkin I, Knauer DJ, Markovic SN. Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc. 2011 Oct; 86(10):981-90.
    View PubMed
  9. Grotz TE, Markovic SN, Erickson LA, Harmsen WS, Huebner M, Farley DR, Pockaj BA, Donohue JH, Sim FH, Grant CS, Bagaria SP, Shives TC, Balch CM, Jakub JW, Mayo Clinic. Mayo Clinic consensus recommendations for the depth of excision in primary cutaneous melanoma. Mayo Clin Proc. 2011 Jun; 86(6):522-8.
    View PubMed
  10. Mansfield AS, Holtan SG, Grotz TE, Allred JB, Jakub JW, Erickson LA, Markovic SN. Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Mod Pathol. 2011 Apr; 24(4):487-94. Epub 2010 Dec 10.
    View PubMed
  11. Wada DA, Law ME, Hsi ED, Dicaudo DJ, Ma L, Lim MS, Souza Ad, Comfere NI, Weenig RH, Macon WR, Erickson LA, Ozsan N, Ansell SM, Dogan A, Feldman AL. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011 Apr; 24(4):596-605. Epub 2010 Dec 17.
    View PubMed
  12. Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, Papotti M, Bussolati G, Lloyd RV. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol. 2010 Sep; 23(9):1269-78. Epub 2010 Jun 18.
    View PubMed
  13. Wood A, Markovic SN, Best PJ, Erickson LA. Metastatic malignant melanoma manifesting as an intracardiac mass. Cardiovasc Pathol. 2010 May-Jun; 19(3):153-7. Epub 2009 Feb 11.
    View PubMed
  14. Asioli S, Erickson LA, Sebo TJ, Zhang J, Jin L, Thompson GB, Lloyd RV. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol. 2010 Jan; 34(1):44-52.
    View PubMed
  15. Cradic KW, Milosevic D, Rosenberg AM, Erickson LA, McIver B, Grebe SK. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab. 2009 Dec; 94(12):5001-9. Epub 2009 Oct 22.
    View PubMed
  16. Asioli S, Erickson LA, Lloyd RV. Solid cell nests in Hashimoto's thyroiditis sharing features with papillary thyroid microcarcinoma. Endocr Pathol. 2009 Winter; 20(4):197-203.
    View PubMed
  17. Erickson LA, Letts GA, Shah SM, Shackelton JB, Duncan LM. TRPM1 (Melastatin-1/MLSN1) mRNA expression in Spitz nevi and nodular melanomas. Mod Pathol. 2009 Jul; 22(7):969-76. Epub 2009 Apr 24.
    View PubMed
  18. Feldman AL, Law M, Remstein ED, Macon WR, Erickson LA, Grogg KL, Kurtin PJ, Dogan A. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia. 2009 Mar; 23(3):574-80. Epub 2008 Nov 06.
    View PubMed
  19. Markovic SN, Erickson LA, Flotte TJ, Kottschade LA, McWilliams RR, Jakub JW, Farley DR, Tran NV, Schild SE, Olivier KR, Vuk-Pavlovic S, Sekulic A, Weenig RH, Pulido JS, Quevedo JF, Vile RG, Wiseman GA, Stoian I, Pittelkow MR, Melanoma Study Group of the Metastatic malignant melanoma. G Ital Dermatol Venereol. 2009 Feb; 144(1):1-26.
    View PubMed
  20. Rumilla KM, Erickson LA, Service FJ, Vella A, Thompson GB, Grant CS, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis: histologic features and growth factor expression. Mod Pathol. 2009 Feb; 22(2):239-45. Epub 2008 Oct 17.
    View PubMed
  21. Rodriguez FJ, Scheithauer BW, Erickson LA, Jenkins RB, Giannini C. Ectopic low-grade adrenocortical carcinoma in the spinal region: immunohistochemical and molecular cytogenetic study of a pediatric case. Am J Surg Pathol. 2009 Jan; 33(1):142-8.
    View PubMed
  22. Erickson LA, Lloyd RV. Familial disorders of the parathyroid gland. Diagn Histopathol. 2009; 15(2):79-86.
    View PubMed
  23. Markovic SN, Suman VJ, Nevala WK, Geeraerts L, Creagan ET, Erickson LA, Rowland KM Jr, Morton RF, Horvath WL, Pittelkow MR. A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study. Am J Clin Oncol. 2008 Dec; 31(6):573-9.
    View PubMed
  24. Sadow PM, Rumilla KM, Erickson LA, Lloyd RV. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors. Endocr Pathol. 2008 Summer; 19(2):97-103.
    View PubMed
  25. Grogg KL, Jung S, Erickson LA, McClure RF, Dogan A. Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior. Mod Pathol. 2008 Jun; 21(6):708-15. Epub 2008 Feb 29.
    View PubMed
  26. Barnhill RL, Argenyi Z, Berwick M, Duray PH, Erickson L, Guitart J, Horenstein MG, Lowe L, Messina J, Paine S, Piepkorn MW, Prieto V, Rabkin MS, Schmidt B, Selim A, Shea CR, Trotter MJ. Atypical cellular blue nevi (cellular blue nevi with atypical features): lack of consensus for diagnosis and distinction from cellular blue nevi and malignant melanoma ("malignant blue nevus"). Am J Surg Pathol. 2008 Jan; 32(1):36-44.
    View PubMed
  27. Markovic S, Suman V, Nevala W, Geeraerts L, Pittelkow M, Ingle J, Creagan E, Kaur J, Erickson L, Rowland K, Morton R, Horvath W. Autologous Anti-Tumor Immunization: A Dose-Escalation Study of Aerosolized Sargramostim (Granulocyte Macrophage Colony Stimulating Factor) in the Treatment of Metastatic Melanoma to the Lung. Am J Clin Oncol. 2008; 31:573-9.
    View PubMed
  28. Erickson LA, Lloyd RV. Utility of immunohistochemical markers in the diagnosis of follicular variant of papillary thyroid carcinoma. Advances In Anatomic Pathology. 2008; 15(1):59-60.
  29. Stilling GA, Zhang H, Ruebel KH, Leontovich AA, Jin L, Tanizaki Y, Zhang S, Erickson LA, Hobday T, Lloyd RV. Characterization of the functional and growth properties of cell lines established from ileal and rectal carcinoid tumors. Endocr Pathol. 2007 Winter; 18(4):223-32.
    View PubMed
  30. Larson JS, Bergstrom LK, Cameron JD, Erickson LA, Grimm TE. Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia. Arch Ophthalmol. 2007 Jul; 125(7):985-6.
    View PubMed
  31. Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007 Jun; 30(3):303-9.
    View PubMed
  32. Erickson LA, Jin L, Nakamura N, Bridges AG, Markovic SN, Lloyd RV. Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas. Cancer. 2007 May 15; 109(10):1965-71.
    View PubMed
  33. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET, Melanoma Study Group of Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc. 2007 Apr; 82(4):490-513.
    View PubMed
  34. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET, Melanoma Study Group of the Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007 Mar; 82(3):364-80.
    View PubMed
  35. Zhang HY, Rumilla KM, Jin L, Nakamura N, Stilling GA, Ruebel KH, Hobday TJ, Erlichman C, Erickson LA, Lloyd RV. Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors. Endocrine. 2006 Dec; 30(3):299-306.
    View PubMed
  36. Shors AR, Kim S, White E, Argenyi Z, Barnhill RL, Duray P, Erickson L, Guitart J, Horenstein MG, Lowe L, Messina J, Rabkin MS, Schmidt B, Shea CR, Trotter MJ, Piepkorn MW. Dysplastic naevi with moderate to severe histological dysplasia: a risk factor for melanoma. Br J Dermatol. 2006 Nov; 155(5):988-93.
    View PubMed
  37. Rumilla KM, Erickson LA, Erickson AK, Lloyd RV. Galectin-4 expression in carcinoid tumors. Endocr Pathol. 2006 Fall; 17(3):243-9.
    View PubMed
  38. Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, Rumilla K, Lloyd RV. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocr Pathol. 2006 Fall; 17(3):213-23.
    View PubMed
  39. Chow LS, Erickson LA, Abu-Lebdeh HS, Wermers RA. Parathyroid lipoadenomas: a rare cause of primary hyperparathyroidism. Endocr Pract. 2006 Mar-Apr; 12(2):131-6.
    View PubMed
  40. Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, Lloyd RV. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol. 2005 Oct; 18(10):1329-35.
    View PubMed
  41. Nakamura N, Carney JA, Jin L, Kajita S, Pallares J, Zhang H, Qian X, Sebo TJ, Erickson LA, Lloyd RV. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest. 2005 Sep; 85(9):1065-75.
    View PubMed
  42. Erickson LA, Lloyd RV, Hartman R, Thompson G. Cystic adrenal neoplasms. Cancer. 2004 Oct 1; 101(7):1537-44.
    View PubMed
  43. Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JKC, DeLellis RA, Harach R, Kakudo K, LiVolsi VA, Rosai J, Sebo TJ, Sobrinho-Simoes M, Wenig BM, Lae ME. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004 Oct; 28(10):1336-40.
    View PubMed
  44. Erickson LA, Myers JL, Mihm MC, Markovic SN, Pittelkow MR. Malignant basomelanocytic tumor manifesting as metastatic melanoma. Am J Surg Pathol. 2004 Oct; 28(10):1393-6.
    View PubMed
  45. Erickson LA, Lloyd RV. Practical markers used in the diagnosis of endocrine tumors. Adv Anat Pathol. 2004 Jul; 11(4):175-89.
    View PubMed
  46. Erickson LA, Jalal SM, Harwood A, Shearer B, Jin L, Lloyd RV. Analysis of parathyroid neoplasms by interphase fluorescence in situ hybridization. Am J Surg Pathol. 2004 May; 28(5):578-84.
    View PubMed
  47. Erickson LA, Papouchado B, Dimashkieh H, Zhang SY, Nakamura N, Lloyd RV. Cdx2 as a marker for neuroendocrine tumors of unknown primary sites. Endocr Pathol. 2004 Fal; 15(3):247-52.
    View PubMed
  48. Erickson LA. Polymorphous light reaction and chronic photosensitivity. Pathology International. 2004; 54(S1):S566-S569.
    View PubMed
  49. Gaffney RL, Carney JA, Sebo TJ, Erickson LA, Volante M, Papotti M, Lloyd RV. Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland. Am J Surg Pathol. 2003 Apr; 27(4):494-8.
    View PubMed
  50. Erickson LA, Papotti M, Volante M, Jin L, Lewis JE, Lloyd RV. Merkel cell carcinomas: Expression of S-phase kinase-associated protein 2 (Skp2), p27, and proliferation markers. Endocr Pathol. 2003 Fal; 14(3):221-9.
    View PubMed
  51. O'Sullivan BP, Erickson LA, Niles JL. Case records of the Massachusetts General Hospital. Weekly clinicopathologic exercises. Case 30-2002. An eight-year-old girl with fever, hemoptysis, and pulmonary consolidations. (Clinical Conference. Journal Article). N Engl J Med. 2002 Sept 26; 347(13):1009-17.
    View PubMed
  52. Erickson LA, Jin L, Papotti M, Lloyd RV. Oxyphil parathyroid carcinomas - A clinicopathologic and immunohistochemical study of 10 cases. Am J Surg Pathol. 2002 Mar; 26(3):344-9.
    View PubMed
  53. Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM, Lloyd RV. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol. 2001 Dec; 25(12):1478-84.
    View PubMed
  54. Erickson LA, Jin L, Sebo TJ, Lohse C, Pankratz VS, Kendrick ML, van Heerden JA, Thompson GB, Grant CS, Lloyd RV. Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms. Endocr Pathol. 2001 Winter; 12(4):429-35.
    View PubMed
  55. Erickson LA, Jalal SM, Goellner JR, Law ME, Harwood A, Jin L, Roche PC, Lloyd RV. Analysis of Hurthle cell neoplasms of the thyroid by interphase fluorescence in situ hybridization. Am J Surg Pathol. 2001 Jul; 25(7):911-7.
    View PubMed
  56. Oliveira AM, Tazelaar HD, Myers JL, Erickson LA, Lloyd RV. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol. 2001 Jun; 25(6):815-9.
    View PubMed
  57. Kendrick ML, Lloyd R, Erickson L, Farley DR, Grant CS, Thompson GB, Rowland C, Young WF Jr, van Heerden JA. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg. 2001 May; 136(5):543-9.
    View PubMed
  58. Lloyd RV, Erickson LA. Cell cycle (cancer). pp. 83-86, 2001. In: McGraw-Hill Yearbook of Science & Technology. 2001. McGraw-Hill, New York, NY. 2001.
  59. Erickson LA, Yousef OM, Jin L, Lohse CM, Pankratz VS, Lloyd RV. p27kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma. Mod Pathol. 2000 Sep; 13(9):1014-9.
    View PubMed
  60. Oliveira AM, Erickson LA, Burgart LJ, Lloyd RV. Differentiation of primary and metastatic clear cell tumors in the liver by in situ hybridization for albumin messenger RNA. Am J Surg Pathol. 2000 Feb; 24(2):177-82.
    View PubMed
  61. Erickson LA, Jin L, Goellner JR, Lohse C, Pankratz VS, Zukerberg LR, Thompson GB, van Heerden JA, Grant CS, Lloyd RV. Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid. Mod Pathol. 2000 Feb; 13(2):186-92.
    View PubMed
  62. Erickson LA. p27(kip1) and other cell-cycle protein expression in normal and neoplastic endocrine tissues. Endocr Pathol. 2000 Sum; 11(2):109-122.
    View PubMed
  63. Erickson L, Yousef O, Jin L, Lohse C, Pankratz V, Lloyd R P27(kip1) expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma. Mod Pathol. 2000; 13(9):1014-1019.
    View PubMed
  64. Erickson LA, Jin L, Wollan P, Thompson GB, van Heerden JA, Lloyd RV. Parathyroid hyperplasia, adenomas, and carcinomas differential expression of p27(Kip1) protein. Am J Surg Pathol. 1999 Mar; 23(3):288-295.
    View PubMed
  65. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol. 1999 Feb; 154(2):313-23.
    View PubMed
  66. Lloyd RV, Erickson LA, Nascimento AG, Kloppel G. Neoplasms causing nonhyperinsulinemic hypoglycemia. Endocr Pathol. 1999 Win; 10(4):291-297.
    View PubMed
  67. Erickson LA, Lloyd RV, Cheville JC. The p27 protein as a diagnostic and prognostic marker in prostate cancer. Current Topics in Clinical Medicine. 1999; 2(3):53-5.
  68. Imamura Y, Jin L, Grande JP, Li CY, Zheng TR, Erickson LA, Lloyd RV. Analysis of TGF-beta and TGF-beta-RII in thyroid neoplasms from the United States, Japan, and China. Endocr Pathol. 1998 Fal; 9(3):209-216.
    View PubMed
  69. Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, Bostwick DG, Lohse CM, Wollan P. Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol. 1998 Apr; 11(4):324-8.
    View PubMed
  70. Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol. 1998 Feb; 11(2):169-74.
    View PubMed
  71. Cheville J, Lloyd R, Sebo T, Cheng L, Erickson L, Bostwick D, Lohse C, Wollan P Expression of p27(kip1) in prostatic adenocarcinoma. Mod Pathol. 1998; 11(4):324-328.
    View PubMed